Health care expenditure growth is affected by important unobserved common shocks such as technological innovation, changes in sociological factors, shifts in preferences and the epidemiology of diseases. While common factors impact in principle all countries, their effect is likely to differ across countries. To allow for unobserved heterogeneity in the effects of common shocks, we estimate a panel data model of health care expenditure growth in 34 OECD countries over the years 1980 to 2012 where the usual fixed or random effects are replaced by a multifactor error structure. We address model uncertainty with Bayesian Model Averaging, to identify a small set of robust expenditure drivers from 43 potential candidates. We establish 16 significant drivers of healthcare expenditure growth, including growth in GDP per capita and in insurance premiums, changes in financing arrangements and some institutional characteristics, expenditures on pharmaceuticals, population aging, costs of health administration, and inpatient care. Our approach allows us to provide robust evidence to policy makers on the drivers that were most strongly associated with the growth in health care expenditures over the past 32 years.
Introduction
In empirical country-level models of health care expenditure (HCE) growth great importance is placed on common factors. These are exogenous influences on expenditure growth that are unobserved but affect all countries in specific time periods. The most prominent common factor is technological change, in particular advances in medical care technology. In addition, changes in sociological factors, lifestyle, epidemiology of diseases, shifts in preferences of patients, and the global economic situation are potentially important drivers of expenditure growth that are absorbed in the common factor if they are unobserved.
Some studies have used proxies for technological change such as R&D expenditures in all sectors or in health care (Okunade and Murthy, 2002) , surgical procedures (Baker and Wheeler, 1998) , the number of specific medical equipment (Weil, 1994) , neonatal survival, or life expectancy and infant mortality (Dreger and Reimers, 2005) . This is problematic because proxies are imperfect and results vary across studies. Therefore most studies still adopt variants of the 'residual approach' (Chernew and Newhouse, 2011 , and references in table 1.3), which was pioneered for the economy in general by Solow (1957) . It measures time-varying observable cost drivers, and generally attributes the rest of spending growth to technology and other common factors. They are captured by the residual for unobserved factors that are assumed to differ across countries, and by a time index (Gerdtham and Löthgren, 2000) , time-specific intercepts (Di Matteo and Di Matteo, 1998) or year fixed effects (Smith et al., 2009) for factors that are assumed common.
Panel data models of HCE growth with year fixed effects rest on the assumption that the association between unobserved common factors and expenditure growth is homogenous.
This implies that the impact of common shocks is assumed to be the same in all countries, and that there is no association between the residual, the unobserved common factors and observed determinants of expenditure growth. These assumptions have been challenged by research demonstrating that countries differ quite markedly in the rate by which they adopt technological innovations in health care (Greenhalgh et al., 2008) , although knowledge innovations are in principle accessible to all, i.e. constitute common shocks. For example, in the adoption of innovation in cardiac procedures countries can be classified into three patterns: early start and fast adoption; late start/fast adoption; and late start/slow adoption (Lyttkens, 2001) . While the literature on HCE growth is extensive, there has not been much progress with incorporating these findings. 3 Our study allows for heterogeneity in the impact of common shocks, to identify the main drivers of HCE growth in OECD countries over the period 1980 and 2012. We estimate a panel data model of HCE growth where the usual fixed or random effects are replaced by a multifactor error structure as proposed by Pesaran (2006) . The factor structure synthesizes the effects of shocks that may hit health spending in different time periods. While those common factors affect in principle all countries, our model allows for their differing impact on growth across countries. The theoretical literature has shown that a multifactor error structure leads to estimates that are less subject to bias.
Main objective of our study is to generate estimates of the most robust drivers of HCE growth. What constitutes 'most robust' has been subject to some debate, because analysis of HCE growth is affected by high model uncertainty. While there is now an impressive amount of evidence on the individual importance of determinants (Chernew and Newhouse, 2011) , there is little guidance for policy makers where to focus cost-containment efforts. We use Bayesian Model Averaging (BMA) to address model uncertainty in HCE growth analysis. It is a technique designed to help account for the uncertainty inherent in the model selection process, something which traditional econometric analysis often neglects. By averaging over many different competing models, BMA incorporates model uncertainty related to choice of regressors into conclusions about parameters and predictions. This technique allows us to identify a small set of highly influential expenditure drivers from the many potential candidates in our data.
In summary, our study offers two methodological contributions to the analysis of HCE growth, to derive results that are more accurate and informative than those from previous studies. We use common factor modelling to allow for heterogeneity in the impact of common shocks, and BMA to address model uncertainty related to choice of regressors.
The improved results are then used to inform policy makers on the magnitude of impact of the most robust drivers of HCE growth.
Background
Recently, the econometrics literature on panel data has focused on common factors that represent unobserved, time-varying heterogeneity that stems from omitted common variables or global shocks that affect each country or observational unit differently (Andrews, 2005; Pesaran, 2006; Bai, 2009; Peng and Forchini, 2014) . Studies are mostly motivated by 4 modelling of economic growth. It is assumed that common shocks affect output directly (through the total factor productivity or Solow residual), but also indirectly via the input in the production process (e.g. through investment decisions). When common shocks have homogeneous effects on the output, the model collapses to the usual time effect. It is the heterogeneity that gives rise to a factor structure. Earlier contributions to the literature allow only for models with factor structure in the errors (Case, 1991; Conley, 1999) for which consistent estimation of the parameters can be done by maximum likelihood procedures or by estimation procedures based on principal components applied to the residuals (Coakley et al., 2006) . More recently, it has been noticed that common shocks are likely to affect both the dependent variable and the regressors and would thus induce endogeneity requiring more sophisticated estimation procedures (Andrews, 2005; Pesaran, 2006) . Pesaran (2006) proposes estimators that are consistent when both the N and T dimensions tend to infinity.
These results have been extended by Bai (2009) to set-ups that allow for a more complex dependence of the regressors on the unknown factors and factor loadings, by Su and Jin (2012) and Huang (2012) to semiparametric models, and by Peng and Forchini (2014) to models for fixed T and N tending to infinity and less restrictive conditions. Common factor models have an obvious application in the analysis of HCE growth because of the importance of common shocks. 1 We use the model proposed by Pesaran (2006) , because we want to allow for the possibility that heterogeneity in the impact of common shocks on HCE growth could -at least partly-be explained by observable factors.
These could relate to the organization of the health system, overall income level or other factors. For example, insurance tends to shield patients from most of the cost of care at the margin and passively reimburses on a disaggregated, fee-for-service basis, which gives greater encouragement to quality and cost-increasing technology in insurance based systems; competition between providers fosters spread of quality improving and cost saving medical technology; higher incomes increase demand for quality and make innovations more profitable to introduce. It is even possible that certain health system traits do not have a great effect on spending growth in themselves, in particular if they change little over time; instead, their impact on spending growth predominantly arises because they are correlated with the common factor, and it is the interaction between the observed system trait and the unobserved common factor which impacts on spending. Identifying determinants of expenditure growth has proven difficult because of high model uncertainty. A large and varied number of potential determinants of expenditures have been suggested (Chernew and Newhouse, 2011) , but for each study that finds evidence for a determinant, there is at least one other study that finds evidence against. Even if there is consensus, there is uncertainty about the magnitude of its impact. For example, nearly all studies uncover rising income-generally proxied by GDP per capita-as an important cost driver, but estimates of the income elasticity of HCEs vary (Hartwig, 2008) . Model uncertainty forces researchers to ignore the uncertainty surrounding the model selection process and base inference on an essentially arbitrary chosen subset of regressors (Moral-Benito, 2010). We use Bayesian Model Averaging (BMA) on least squares estimation as proposed by Sala-i-Martin et al. (2004) extended to a panel data framework to estimate all model specifications given our data. We then examine whether the estimated results for any determinant are sufficiently stable ('robust') across most specifications. By doing so, we are considering not only the uncertainty associated with the parameter estimate conditional on a given model, but also the uncertainty of the parameter estimate across different models. This approach leads us to more reliable, or at least more honest, conclusions regarding the significance of the estimated effect of a determinant (Moral-Benito, 2010).
A recent paper by Hartwig and Sturm (2014) applies frequentist model averaging to the analysis of HCE growth for 33 OECD countries over the period 1970-2010. They test a large number of macroeconomic and institutional determinants of HCE growth. Results 6 confirm earlier findings that GDP growth and a variable representing Baumol's 'cost disease' theory emerge as robust and statistically significant determinants of HCE growth. Depending on whether or not outliers are excluded, there are six additional robust drivers: the growth in expenditure on health administration, the change in the share of inpatient expenditure in total HCE, the (lagged) government share in GDP, the change in the insurance coverage ratio, the growth in land traffic fatalities and the growth in the population share undergoing renal dialysis.
Data
Main data source for our study is the OECD Health Statistics (OECD, 2014), supplemented with institutional variables of the organisational features of healthcare systems.
These are binary variables, obtained from Christiansen et al. (2006) and extended to the year 2012 by us. In total, our study tests 43 determinants in 34 countries between 1980 and 2012. Table I lists countries and years with data available, and Table II presents variable descriptions and summary statistics. We broadly follow Hartwig and Sturm (2014) in choice of determinants, but include additional ones as suggested in the literature. We follow common practice and convert all level variables into growth rates and all proportion/share variables into first differences.
Insert Table I Here
The presence of missing values in the OECD data poses a problem. In order to expand the number of drivers that we can test for importance, and investigate changes in expenditures over a relatively long period from 1980 to 2012, we impute missing values for determinants with multiple imputation (MI) (STATA, 2013; Azur et al., 2011) . We do not impute the dependent variable but drop country-years with missing values, thus creating an unbalanced panel (see Table I for available country-years). MI predicts the missing data in a manner that allows for uncertainty about the values of the missing data, while at the same time maintaining the overall covariance structure of the variables (for more details see online Appendix II A). This ensures that causal inferences are not being driven by the randomness of a given imputation. MI adjusts the standard errors in the estimated relationship, to account for the fact that there is additional uncertainty relating to the imputation (Rubin, 1987) . Table II and III show that original and imputed data are 7 sufficiently similar 2 . We only analyse determinants if less than 50% values are missing across country-years. In an alternative specification, we applied a cut-off at 25%, which reduces the number of determinants from 43 to 24. With multiple imputation, a greater uncertainty related to the imputation results in an increase of the standard deviation around the estimates and makes determinants less likely to be significant (White et al., 2011) . This implies that the results will reflect a weaker evidence base due to missing values, and we would argue that this is a desirable feature for policy decisions. 
Summary statistics presented in

Insert
Econometric Framework
The innovative contributions of our study are to account for heterogeneity in the effects of common factors by allowing a multifactor error structure, and to address model uncertainty with the use of Bayesian Model Averaging. These innovations allow us to determine drivers that are most strongly associated with the growth in HCE. A panel data model of HCE growth with multifactor error structure (Pesaran, 2006; Bai, 2009 ) can be written as , 1,..., ; 1,...,
where y it is HCE growth in country i and time period t; is a vector of regressors and represents the heterogeneous coefficients for the i-th country, which follow the random coefficient specification, i.e., ,~IID(0, ), for 1,2
. The error term is assumed to have a multiple factor structure ,
is a 1 m vector of factor loadings and is an idiosyncratic error with 2 Figure A1 in online Appendix II shows overlay plots of original and imputed data for selected variables, which further demonstrate imputed data are sufficiently similar to original data.
mean of zero and assumed to be uncorrelated with the regressors in it
x . 3 While a conventional panel data model allows for common shocks, it makes the restrictive assumption that they affect all countries in the same way. The factor structure represents a generalization of the conventional error components approach in the sense that it allows for unobserved time-specific factors to affect all countries in different ways; for example, it allows for variations in the rates by which countries adopt or implement new technology that becomes generally available in specific time periods.
Some of the causes of unobserved heterogeneity in the effects of common shocks remain unobserved, and would then be absorbed in the factor loadings. Therefore, in addition, 
where the posterior probability of Following Leamer (1978) , the posterior variance of is given by
The posterior variance of  incorporates not only the weighted average of estimated variances from each individual model, but also the weighted variances in estimates of  across different models. Following Sala-i-Martin et al. (2004), we apply the so-called BACE (Bayesian Averaging of Classical Estimates) approach. In this approach, a diffuse prior is assumed for a given model 
where ˆr  is the generic OLS estimator for  from model r M . By applying common factor model to our study, ˆr  is the PCCE estimator.
The logic of Bayesian inference is to obtain results for every possible model given the data, and average them. The weights in the averaging are the posterior model probabilities.
The logic is straightforward, but implementation can be difficult when 2 K (the number of models under consideration) is large. It is then practically impossible to incorporate every possible model in the averages as given by Equations (3) and (4). This has led to the development of various algorithms that do not require estimating all possible models and instead approximate results (Madigan, et al. 1995; George and McCulloch 1993 ; Geweke r M  10 1999; Clyde, et al. 1996) . In this study we adopt the 'stratified sampling' 4 method proposed by Sala-i-Martin, et al. (2004) .More details on Bayesian Model Averaging are provided in online Appendix II B. (3) and (4) respectively. From the posterior density we estimate the posterior probability that a variable's coefficient has the same sign as its posterior mean conditional on inclusion, which is indicated as "Sign Certainty Probability". If sign certainty is above 95%, then the coefficient would be 10-percent significant in a two-tail test in classical terms, and we can be 90% confident that the variable is a robust driver of HCE. We further report the fraction of specifications for which the absolute value of a determinant's t-statistic is larger than 2. 5 Table AII in online Appendix II presents results for the model with variables that have less than 25% missing values. In the following discussion we do not mention the 25% sample results if the respective variable was either excluded from analysis, or not robust.
Results
Insert Table IV Here
Results on robustness do not directly inform on the policy importance of a determinant. Estimates of the magnitude of impact of robust determinants on HCE growth are compared in Table IV . This shows the percentage change in growth rate associated with a one within-country standard deviation (SD) change of the determinant. We use a one SD change in determinants -instead of a one unit change-to makes determinants comparable that are measured in different units or that vary in range. Results for determinants that are not robust are presented in figure 1 . 6 Sign certainty is plotted on the x-axis, and in order to allow interpretation as 'Probability of determinant being positive', the values are subtracted from unity for determinants with a negative posterior mean. The fractions of significant specifications are plotted on the y-axis.
Insert Figure 1 Here 11 We can identify 16 robust variables from the CF models (7 robust variables for the 25% models). Growth in GDP is positively associated with expenditure growth, confirming results from many previous studies that income is a critical factor in determining how much nations spend on medical care (Chernew and Newhouse, 2011) . It consistently explains around 90% of variation in real health spending across countries and time (Smith et al., 2009) . Empirical estimates tend to find a macro-level income elasticity of about 1.0 after adjusting for other factors that are correlated with GDP such as technology, medical prices and insurance, implying that health spending moves in tandem with GDP (Gerdtham and Jönsson, 2000) .
More recent studies estimate elasticities of below one, suggesting the necessity nature of healthcare (Dreger and Reimers, 2005; Baltagi and Moscone, 2010) . This is confirmed by our results; a one SD increase in GDP growth rate is associated with a .77 increase in HCE growth rate. The posterior means of GDP from the 50% and 25% models are nearly identical.
Growth in insurance premiums for private and social insurance is positively associated with growth in HCE; insurance payments make up part of measured healthcare expenditures, and growth in premiums are likely to directly translate into HCE growth.
Impact is largest among all robust regressors at a 1.31 increase in HCE growth. However, changes in the two variables that capture the proportion of health expenditures funded by social and private insurance are negatively associated with HCE growth; i.e. countries that have re-oriented their health system towards a greater role of social or private insurance in financing, and by default a smaller role for public financing, have experienced a reduction in HCE growth. According to our results, increases lead to 0.96 and 0.51 reductions in HCE growth, respectively. Research on the expenditures impact of social and private health insurance is conflicting, for a discussion in the context of OECD countries see Colombo and Tapay (2004) . On the one hand, private insurers operating in a competitive market may improve efficiency in administering insurance plans and enforce pressures on health service providers to minimise costs. On the other hand, coverage provided by multiple competing insurers can be administratively costly, and market failures resulting from information asymmetries and moral hazard may ultimately increase costs.Our results for private insurance would support the first line of arguments. Tax financed systems are generally less regressive than systems relying on insurance for financing, in particular private insurance, because contributions can be spread over a larger share of the population (Wagstaff et al., 1999) . The dampening impact of a greater role for insurance financing on HCE growth may therefore come at a political cost of increased inequality. For a discussion, see (Chernew and May) .
An increase in pharmaceutical sales per capita is positively associated with healthcare expenditure growth. Pharmaceuticals account for almost a fifth of all health spending on average across OECD countries (Docteur et al., 2008) , and diffusion of new drugs has been an important factor contributing to increased pharmaceutical expenditure and overall HCE (Docteur et al., 2008; Clemente et al., 2008) . However, the relationship between pharmaceutical spending and total health spending is a complex one, in that increased expenditure on pharmaceuticals to tackle diseases may be offset by reduced morbidity, less need costly interventions in future, and overall improved health outcomes (Dormont et al., 2006) . This is not an effect we can analyse, and we find the impact of pharmaceuticals to be comparably high at 0.83 increase in HCE growth. An increase in the proportion of the population above 65 years is associated with an increase in HCE growth at0.4.The posterior mean is very similar in the 25% sample (2.82 versus 3.00). A straightforward explanation seems to be the greater morbidity among the elderly population, but some have contested this based on evidence that the impact of age disappears once proximity to death is controlled for (Zweifel et al., 2004) . Healthcare resource use is most intense in the few months before death, and medical expenses during additional life years spent in relatively good health may hardly impact on overall lifetime spending. The unemployment rate is negatively associated with expenditure growth, i.e. an increase in the unemployment rate is associated with a decrease in HCEs. Unemployment rises in times of financial crises, and associated reductions in tax revenue and increases in the social budget devoted to unemployment benefits and other social contributions have been found to reduce public funds for healthcare (Cylus et al., 2012; de Belvis et al., 2012) . Similarly, recessions slow the growth in wages with negative impact on private healthcare expenditures. Growth in public spending on education and expenditures of general government are positively associated with healthcare spending, indicating that spending across different public services is complementary rather than substitutive.
Associations are 0.46 and 0.34, but the determinants are significant in only 88% and 53% of all specifications.
Inpatient care discharges and acute care beds are positively associated with HCE growth. Most countries have made efforts to substitute inpatient care with less costly outpatient and day case treatments, and our result show that countries which were more successful with this substitution have indeed profited from a slower growth in HCE.
Reductions are associated with0.35and 0.28reductions in HCE growth (at low significance for beds though). This result is confirmed by previous findings (Docteur and Oxley, 2003) .
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An increase in the costs of expenditures on health administration is positively associated with expenditure growth although the effect is small at 0.35. Our results confirm previous evidence (Hartwig and Sturm, 2014) . In some countries, administration account for a sizable proportion of the health care budget. Highest costs are recorded for the USA, at around 31.0 percent of HCE in the United States. Rates are lower in most other countries, for example just under 17% in Canada (Woolhandler et al., 2003) .The authors have estimated that moving to a Canadian-style social insurance system would reduce U.S. administrative costs by 10-15 percent of total health spending, confirming our result. Inpatient expenditure is negatively associated with HCE. This is a counterintuitive result that is difficult to explain, and also found by Hartwig and Sturm (2014) , however, it is significant in less than 80% of specifications. Tobacco consumption has a robust positive association with HCE growth, but only 46% of specifications are significant.
A change towards, or away from, capitation remuneration and a public contract healthcare system are the only institutional determinants associated with a robust increase, or decrease, in HCE growth, however the effects are small at 0.22 and 0.05, and less than 90% of specifications are significant. The posterior means are very similar for the 25% models; for capitation 2.35 (versus 1.92), and for public contract systems 2.35 (versus 2.30). Capitation is usually considered as cost-containing, which is not supported by our result. However, it has been found that there are great variations in the way capitation is implemented (Rice and Smith, 2001) . Public contract systems are generally considered less successful in containing healthcare cost than public integrated systems, mainly because payment of providers is expost (Docteur and Oxley, 2003) . This is confirmed by our finding. None of the other institutional variables are significant drivers of healthcare expenditures. This could be due to difficulties of measuring health system characteristics in binary variables, and also because there is relatively little change in such characteristics over time, and identification has mainly to rely on cross country variation.
There are a few determinants that nearly reach robustness and statistical significance (see figure 1) . These are choice of hospital, GP or specialist, road traffic accidents and alcohol consumption, and at lower levels of significance, R&D expenditures and insurance coverage. Apart from those, sign certainty and fraction significant are low for the remaining determinants. Results from fixed effects and CF models are very similar, although four determinants are robust according to CF but not FE models, and one robust according to FE but not CF model. 14
Conclusions
Empirical models of healthcare expenditure growth are affected by at least three problems: unobserved heterogeneity in the effect of common shocks across countries, high model uncertainty, and missing data. Economic theory has shown that these problems may lead to bias in the estimates of the impact of observable cost drivers, and could be partly responsible for the relative wide variations in results that have been found in the literature.
Objective of our study is to address these problems by applying novel econometric methods that have been developed in the empirical economic growth literature. The innovative contributions of our study to the analysis of HCE growth are, first, to adopt panel data models with a multifactor error structure (Pesaran, 2006; Bai, 2009 ) that allows for variations in the impact of common shocks on HCE growth across countries; second, to apply Bayesian model averaging methods (Koop et al., 2007) that address model uncertainty and identify robust drivers of healthcare expenditure growth; third, to use multiple imputation techniques (Rubin, 1987 ) that incorporate the uncertainty surrounding the imputation into final model estimates.
We compare our results with a standard fixed effects model of HCE growth, and find that estimates are very similar, at least for the most robust determinants. This lets us conclude that despite the supremacy of CF models on theoretical grounds, in this practical application a standard FE model seems perfectly adequate. The finding could also mean that there is homogeneity in the impact of common shocks, or that the CF model is unable to correct for heterogeneity, in our application.
Our analysis has limitations. For many of our results it would be erroneous to infer a direct causal relation between a change in the determinant and impact on HCE growth. Some determinants may act as proxies for others that are not included in the models, or the relationship is highly complex and influenced by other factors. Our data is affected by unobserved variables and missing data. Although the OECD Health Statistics is the preferred dataset for analysis of HCE growth, some important drivers, in particular institutional variables, are poorly represented. Our results are based on historical trends over the past 32 years, and may not apply to the coming 32 years. Pesaran's estimator makes the implicit assumption that is that the error cross-section dependence in large N and large T panels can be explained by exogenously given unobserved factors which are essentially treated as nuisance parameters that have no informational content. The extensive previous literature on healthcare expenditure growth largely rests on the assumption that there is no cross-section 15 dependence at all. Therefore we consider our approach an improvement over previous studies, but of course we acknowledge that future research should address this issue. Bayesian Model
Averaging does not address model uncertainty related to functional form, and it is subject to the available data.
Despite the limitations, we can derive some conclusions. A greater reliance on private and social insurance, as opposed to public financing, seems to dampen growth. Competitive pressures in insurance markets seem to be associated with greater efficiency. Tackling the costs of pharmaceuticals, by regulation of the pharmaceuticals and devices markets, is another promising policy according to our results. Similarly, slimming health administration is predicted to curtail growth. Organisational reforms of the healthcare system should be directed to increase efficiency of the management of healthcare provision; further research is necessary to establish at what managerial level greatest efficiency gains can be expected. We further find that substitution of inpatient with outpatient care can reduce HCE growth, a policy that has been fostered by most countries in our study. Characteristics of the healthcare system and health indicators show weak associations with HCE growth, but it is important to keep in mind that these factors may still have an association with the level of expenditures.
Overall, we hope that our results provide robust evidence to policy makers on the drivers that are most strongly associated with the growth in HCE, and will be used to inform effective policies in OECD countries. 
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Figure 1 Non-robust Determinants of Healthcare Expenditure Growth
Note: Figure displays only determinants with sign certainty <0.95 and >0.05; sign certainty is increasing towards the right (for positive determinant) and left (for negative determinants); significance is increasing towards the top of the figure. Sign certainty probability -probability that coefficient estimate is positive
